Brokers Issue Forecasts for Krystal Biotech FY2024 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $3.64 per share for the year, down from their prior forecast of $4.01. HC Wainwright currently has a “Buy” rating and a $221.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2024 earnings at $1.81 EPS, FY2025 earnings at $5.57 EPS, FY2027 earnings at $9.34 EPS and FY2028 earnings at $9.76 EPS.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. The company’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.67) earnings per share.

KRYS has been the topic of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday. Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Finally, Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $197.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $185.45 on Thursday. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of 104.77 and a beta of 0.82. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34. The company’s 50-day moving average is $181.20 and its 200 day moving average is $180.29.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of KRYS. EFG Asset Management North America Corp. increased its stake in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares in the last quarter. GAMMA Investing LLC increased its stake in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after acquiring an additional 94 shares during the period. Arizona State Retirement System lifted its position in shares of Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after acquiring an additional 108 shares in the last quarter. Finally, Fiera Capital Corp boosted its stake in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after acquiring an additional 130 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).